Inactive Instrument

Nuo Therapeutics, Inc. Stock Other OTC

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 112K 154K Sales 2023 609K 835K Capitalization 24.33M 33.39M
Net income 2022 -3M -4.12M Net income 2023 -3M -4.12M EV / Sales 2022 543 x
Net cash position 2022 1.72M 2.35M Net cash position 2023 673K 924K EV / Sales 2023 38.9 x
P/E ratio 2022
-18.9 x
P/E ratio 2023
-7.3 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 39.31%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 08-09-18
Chief Operating Officer 58 08-08-31
Members of the board TitleAgeSince
Director/Board Member 67 09-01-29
Chief Executive Officer 61 08-09-18
Director/Board Member 75 17-04-06
More insiders
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW